Unique ID issued by UMIN | UMIN000002468 |
---|---|
Receipt number | R000003006 |
Scientific Title | A Phase 2 Study of Pemetrexed in Elderly Patients with Previously Untreated Non-Squamous Non-Small-Cell Lung Cancer |
Date of disclosure of the study information | 2009/09/09 |
Last modified on | 2013/02/27 18:54:54 |
A Phase 2 Study of Pemetrexed in Elderly Patients with Previously Untreated Non-Squamous Non-Small-Cell Lung Cancer
A Phase 2 Study of Pemetrexed in Elderly Patients with Previously Untreated Non-Squamous Non-Small-Cell Lung Cancer
A Phase 2 Study of Pemetrexed in Elderly Patients with Previously Untreated Non-Squamous Non-Small-Cell Lung Cancer
A Phase 2 Study of Pemetrexed in Elderly Patients with Previously Untreated Non-Squamous Non-Small-Cell Lung Cancer
Japan |
Elderly patients with previously untreated non-squamous non-small cell lung cancer
Pneumology |
Malignancy
NO
To evaluate efficacy and safety of pemetrexed for elderly patients with previously untreated non-squamous non-small cell lung cancer
Safety,Efficacy
Confirmatory
Phase II
Response rate
Progression free survival
Overall survival
Disease control rate
Safety
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Pemetrexed(500mg/m2) day 1,q3w until disease progression
75 | years-old | <= |
Not applicable |
Male and Female
1)Histologically or cytologically proven non-squamous non-small cell lung cancer
(without large cell neuroendocrine carcinoma)
2)Non-squamous non-small cell cancer patients with stage IIIB(with pleural dissemination or malignant pleural effusion),stage IV or recurrent disease after surgery,who have no prior chemoterapy
3)With measurable lesion
4)If the patient underwent radiotherapy, there should be the following interval between the radiotherapy and the registration
i)Radiotherapy including pulmonary field ->3 months
ii)Radiotherapy other than thoracic radiation ->1 month
5)75 years or older
6)ECOG PS 0-1
7)Adequate organ function
8)Life expectancy more than 3 months
9)Written informed consent
1)Interstitial pneumonia or pulmonary fibrosis detectable on CT scan
2)History of drug induced interstitial pneumonia
3)History of severe drug allergy
4)History of active infection or other serious disease condition
(GI bleeding,etc.)
5)History of poorly controlled pleural effusion,pericardial effusion and ascites
6)History of severe heart disease(uncontrollable arrythmia,uncontrollable angina pectoris,herat failure,etc.)
7)Uncontrollable diabetes mellitus
8)History of symptomatic brain metastases
9)Hystory of active double cancer
10)History of active psychological disease
11)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
45
1st name | |
Middle name | |
Last name | Yoshikazu Kotani |
Kobe University Hospital
Department of Respiratory Medicine
7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
078-382-5846
1st name | |
Middle name | |
Last name | Yoshiiro Hattori |
Hyogo Cancer Center
Department of Thoracic Oncology
13-70, Kitaouji-cho, Akashi, Hyogo 673-8558, Japan
078-929-1151
hattori@hp.pref.hyogo.jp
Kobe Lung Cancer Study Group
None
Self funding
NO
神戸大学医学部附属病院(兵庫県)
先端医療センター(兵庫県)
兵庫県立がんセンター(兵庫県)
2009 | Year | 09 | Month | 09 | Day |
Partially published
Completed
2009 | Year | 08 | Month | 10 | Day |
2009 | Year | 08 | Month | 01 | Day |
2012 | Year | 06 | Month | 01 | Day |
2009 | Year | 09 | Month | 07 | Day |
2013 | Year | 02 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003006